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Brown: Repurposing Old Drugs for New Uses

REPURPOSING OLD DRUGS FOR NEW USES
I. INTRODUCTION
Despite recent advancements in the drug discovery and
development process, it is still lengthy, expensive, and prone to
failure. Developing and bringing a new drug to market costs an
estimated $2.558 billion' and takes, on average, twelve to sixteen
2
years. This lengthy and expensive process, however, does not
seem to have any advantages in terms of the number of approved
drugs as it is approximately twenty-seven per year.3 As Part II will
explain, it is clear why the cost and time for doing so are
extremely high. Drug repurposing, however, is able to more
quickly and efficiently bring new drugs to market. Part II explains
the usual drug development process and why so few drugs actually
enter the market. Part III explores the process of drug repurposing,
how it facilitates faster and more efficient drug development, as
well as the advantages and disadvantages of utilizing this process.
Part IV elaborates on how drug repurposing is currently being
utilized.
Part V examines whether drug repurposing could
constitute patent infringement. Part VI analyzes the different

' Joseph A. DiMasi et al., Innovation in the pharmaceuticalindustry: New
estimatesofR&D costs, 47 J. HEALTH ECON. 31 (May 2016). Note that this
number increased from $1.2 billion in 2007. See Joseph A. DiMasi & Henry G.
Grabowski, The Cost ofBiopharmaceuticalR&D. Is Biotech Different?, 28
MANAGERIAL &DECISION ECON. 469, 475, 476-77 (2007). Some research
suggests it could cost as much as $4 billion. See Garret A. FitzGerald, ReengineeringDrug Discovery andDevelopment, 17 LEONARD DAVIS INST. OF
HEALTH ECON. 1, 1 (2011).
2 See UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE (GAO), NEW
DRUG DEVELOPMENT: SCIENCE, BUSINESS, REGULATORY, AND INTELLECTUAL
PROPERTY ISSUES CITED AS HAMPERING DRUG DEVELOPMENT EFFORTS 1, 6

(2006) (estimating drug development takes approximately fifteen years); Joseph
A. DiMasi, New Drug Development in the UnitedStates from 1963 to 1999, 69
CLINICAL PHARMACOLOGY & THERAPEUTICS 286, 292 fg. 6 (2001).
1 Nicola Nosengo, New tricksfor old drugs, 534 NATURE 315 (June 16, 2016),
http://lib.shsmu.edu.cn/Assets/userfiles/sys_1 83695/files/5343 14a.pdf.

1

Published by Via Sapientiae, 2017

1

DePaul Journal of Art, Technology & Intellectual Property Law, Vol. 28, Iss. 1 [2017], Art. 2

2

DEPAULJ ART, TECH. &IPLAW

[Vol. XXVIII:l

routes through which repurposed drugs can achieve market
exclusivity-Food and Drug Administration (FDA) exclusivity
and patent exclusivity. Part VII then discusses the areas in which
drug repurposing can be improved so as to allow drug developers
to facilitate higher utilization. Part VIII concludes.
II. PHARMACEUTICAL DRUG DEVELOPMENT
MARKET FAILURE
Part A explains the usual drug development process and
why the process is so lengthy. Part B then discusses why so few
drugs successfully complete the lengthy drug development process
and enter the market.
A. The Usual Drug Development Process
Typical drug development proceeds through four phases:
(1) basic research, (2) preclinical trials, (3) clinical trials, and (4)
FDA New Drug Application (NDA) filing and approval.4 Basic
research involves biological screening and pharmacologic testing,'
pharmaceutical dosage formulation and stability testing, 6 and
toxicology and safety testing.7 Preclinical trials, conducted on at
least two animal species, establish the drug's toxicological and
pharmacological profile. The test results determine whether it is
4 See BiopharmaceuticalResearch & Development: The ProcessBehind New
Medicines, PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AM. 18

(2015), http://www.phrma.org/sites/default/files/pdf/rdbrochure_022307.pdf
for a visual depiction of the drug development process.
s "These are studies to explore the pharmacological activity and therapeutic
potential of compounds." Regulatory Science, UNIv. S. CAL.,

https://regulatory.usc.edu/consulting/resources/drugs/basic-research/ (last
visited Dec. 1, 2016).
6 This is the "process of turning an active compound into a form and strength
suitable for human use." Id
' These are "[t]ests to determine the potential risk a compound poses to
animals, tissue cultures, and other test systems prior to their human
introduction." Id.

https://via.library.depaul.edu/jatip/vol28/iss1/2
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reasonably safe to proceed with human trials;' if the results
indicate it is reasonably safe, then drug development moves into
human clinical trials. These trials consist of three phases, each
with their own testing purpose.' Phase I tests the safety of the
drug, Phase II tests its efficacy, and Phase III involves the blind
testing of the drug in one to two thousand patients.' 0 If all goes
well during clinical trials," the pharmaceutical company files a
New Drug Application (NDA) for FDA approval. In order to
receive FDA approval, "[tihe FDA requires extensive [data from
the] clinical trials demonstrating a new drug's safety and efficacy
for at least one indication before that drug can enter the market."

8

PreclinicalTrial, UNIV. S. CAL.,

https://regulatory.usc.edu/consulting/resources/drugs/preclinical/ (last visited
Dec. 1, 2016).
9 See FAQ ClinicalTrials.gov- Clinical TrialPhases, U.S. NAT'L LIBRARY OF
MEDICINE, https://www.nlm.nih.gov/services/ctphases.html (last updated Apr.
18, 2008); ClinicalTrials 101, CROHN'S & COLITIS FOUND. OF AM.,
http://www.ccfa.org/resources/clinical-trials101.html?referrer-https://www.google.com/ (last accessed Dec. 1, 2016). Note
that the FDA Modernization Act of 1997 allows the FDA to base its approval of
a NDA on data from one adequate and well-controlled clinical investigation and
confirmatory evidence. 21 U.S.C. § 355(d). This would allow a drug developer
to complete only one phase of clinical trials; however, the "FDA has in practice
implemented this provision only when the single adequate and well-controlled
clinical investigation has statistical significance that is an order of magnitude
greater than is normally required." Peter Barton Hutt, The Regulation ofDrug
Products by the United States Foodand DrugAdministration, in THE
TEXTBOOK OF PHARMACEUTICAL MEDICINE 585 (John P. Griffin & John
O'Grady eds., 5th ed. 2006).
'0 See FAQ ClinicalTrials.gov-Clinical TrialPhases, supranote 9.
" Drugs fail during clinical trials either because the drug is not safe or it is
ineffective. See JP Hughes et al., Principlesof Early Drug Discovery, 162
BRITISH J. PHARMACOLOGY 1239, 1239 (2011).
12 Benjamin N. Roin, Solving the Problem of New Uses 21 (Oct. 18, 2016),
https://www.bu.edu/law/files/2016/10/Solving-the-Problem-of-New-Uses-Benn.-Roin.pdf (draft). An indication is the particular use for which the drug is
approved. Approved Drug Uses, PUBMED HEALTH (Aug. 20, 2015),
https://www.ncbi.nlm.nih.gov/pubmedhealth/approved-drug-uses/.
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Adding to the already lengthy process, FDA approvals take, on
average, two to three years to review all of the data and issue a
decision. 13
B. A Long Processfor Minimal Results
Unfortunately, most pre-clinical drug candidates do not
survive human clinical trials. Of five thousand pre-clinical drug
candidates, on average five will survive to human clinical trials,
and only one will receive NDA approval.1 4 Stated another way,
only approximately 0.02% of all drugs tested are approved and
enter the market. " Further exacerbating this problem,
pharmaceutical companies spend billions of dollars on research
and development for drugs that ultimately never make it out of
clinical trials. This then translates into higher drug prices for
consumers. Dov Greenbaum, intellectual property attorney and
Associate Professor at Yale University, asserts "[t]he high failure
rate of potential compounds is a huge component of the costs of
drugs."
This gap between the thousands of pre-clinical candidates
arising out of basic research and the few that actually enter the
market is known as the "Valley of Death."' 7 Drug repurposing, 8
however, can potentially bridge this valley by more efficiently and
successfully bringing drugs to the market.

1

Hutt, supra note 9, at 585.

Daniel S. Sem, Comment, Repurposing -Finding New Usesfor Old (And
Patented)Drugs:Bridging the "Valley ofDeath, " to TranslateAcademic
Research into New Medicines, 18 MARQ. INTELL. PROP. L. REv. 139, 147
14

(2014).
s Katherine S. Gaudry, Evergreening: A Common Practice to Protect New
Drugs 1 (May 30, 2011) (on file with Harvard University DASH system).
16 Dov Greenbaum, Incentivizing PharmacogenomicDrug Development: How
the FDA Can Overcome Early Missteps in RegulatingPersonalizedMedicine,
40 RUTGERS L.J. 97, 111 (2008).
1 Sem, supra note 14, at 146.
Drug repurposing is also known as drug rediscovery, reusing, and
repositioning.

https://via.library.depaul.edu/jatip/vol28/iss1/2
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II. DRUG REPURPOSING AS A SOLUTION
Drug repurposing is an alternative strategy for stimulating
drug innovation, which could be part of the solution to bringing
more drugs to the market and lowering the cost of both drug
Repurposing is the
development and the drugs themselves.
process of studying existing drugs to see if they are safe and
effective for treating other diseases or illnesses than the one(s) for
which they were originally produced.19 Essentially, it is the
process of using old drugs for new uses. Historically, repurposing
has occurred by chance observation. For example, Viagra was
developed for heart disease, but became a blockbuster drug 2 0 for
erectile dysfunction after researchers noticed clinical trial patients
maintained erections for a longer period of time while taking the
drug.2 ' Consequently, repurposing is now a systematic approach
to drug innovation, with pharmaceutical drug collections and
librarieS2 2 offering scientists thousands of drugs to screen and test
for new uses.2 3
'9 Sem, supra note 14, at 147.
20 "Blockbuster drug" refers to "medicines that bring in more than $1 million in

sales every year.. . They can make a pharmaceutical company and send them to
rock-star status among investors." Laura Lorenzetti, 7 New Blockbuster Drugs
to Watch in 2016, FORTUNE (Mar. 25, 2016),
http://fortune.com/2016/03/25/new-blockbuster-drugs-to-watch/.
21 Julia Kollewe, Why finding new uses for old drugs is a growing business,
THE GUARDIAN (Nov. 27, 2012, 1:14 PM),
https://www.theguardian.com/business/2012/nov/27/new-uses-old-drugsbusiness.
22 Drug collections and libraries are collections of stored drugs which allow
drug discovery via high throughput screening of the "entire compound library
directly against the drug target." Hughes, supra note 11, at 1242. "The
screening paradigm involves the use of complex laboratory automation .. . to
identify molecules that interact with the drug target." Id. The drug collections
and libraries can be owned by private companies, such as pharmaceutical
companies, and universities. Id
23 Curtis R. Chong & David J. Sullivan Jr., New usesfor old drugs, 448
NATURE 645 (Aug. 2007).

Published by Via Sapientiae, 2017

5

DePaul Journal of Art, Technology & Intellectual Property Law, Vol. 28, Iss. 1 [2017], Art. 2

DEPAULJ. ART, TECH. &IPLAW

6

A.

[Vol.XXVIII:1

The RepurposingDrug Development Process

Drugs may be repurposed for new uses, such as a new
indication, dosage form, regimen or route of administration, or a
new target patient population.25 The drug to be repurposed can be
FDA approved and currently in use (on or off patent), 26 approved
but no longer in use (also called "shelved"), or unapproved by the
FDA ("failed" drugs that did not pass clinical trials or receive FDA
approval).
The process of repurposing begins when a researcher
chooses a drug from a pharmaceutical library, 2 7 such as the
Prestwick Chemical Library in Washington D.C. 28 or Harvard
Medical School's NINDS Custom Collection 2,29 to study the drug
for treatment of a specific indication. There are essentially two
A drug indication is a "particular use for the drug, such as treating asthma."
Approved drug uses, PUBMED HEALTH (Aug. 20, 2015),
24

https://www.ncbi.nlm.nih.gov/pubmedhealth/approved-drug-uses/.
25

Ned Israelsen, New Patentsfor Old Drugs, PHARMA Focus

ASIA,

https://www.pharmafocusasia.com/strategy/new-patents-old-drugs (last
accessed Nov. 28, 2016). Note that drugs can be prescribed for off-label uses
(those uses of which a pharmaceutical would likely repurpose and seek
approval) without violating any law. See U.S. v. Caronia, 703 F.3d 149, 166

(2d Cir. 2012).
26
27

On or off patent refers to whether the drug is currently protected by a patent.
See Dorothea Emig et al., Drug Target PredictionandRepositioning Using

an IntegratedNetwork-BasedApproach, 8 PLOS ONE e60618 (Apr. 2013),
http://images.info.science.thomsonreuters.bizlWeb/ThomsonReutersScience/%7

Bc9082186-f3fc-4623-8953-573a8a4cbbOf/7DDrug TargetPrediction.pdf.
28 See A Recognized Chemical ScreeningLibrary, PRESTWICK CHEMICAL
http://www.prestwickchemical.com/prestwick-chemical-library.html
(last accessed Dec. 1, 2016).
29 See NINDS Custom Collection 2, HARVARD MED. SCH.,
http://iccb.med.harvard.edu/ninds-custom-collection-2 (last accessed Apr. 10,
2017) (The collection was originally compiled by MicroSource Discovery
Systems for the National Institute of Neurological Disorders and Stroke
(NINDS), the Huntington's Disease Society of America, the Amyotrophic
Lateral Sclerosis Association, and the Hereditary Disease Foundation.)
LIBRARY,
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ways to repurpose drugs: (1) the researcher can create new
formulations or indications for a previously shelved active
pharmaceutical ingredient (API); or (2) the researcher can create
new formulations or indications for existing market drugs. 30 The
first approach is the more attractive option, because any patents
covering the old drug were likely filed many years ago and are
near expiration or already expired at the time of repurposing.3 1 It
is worth noting that while the industry struggles to deliver twentyseven drugs to the market each year, as of 2012, there were
approximately 25,000 drugs off-patent that could be studied for
repurposing.3 2 Under the second approach, the drug will likely
face a "patent thickets" problem 33 as the drug is probably still on
patent, which requires licensure or clearing any patents on the drug
before it can be studied. This option makes repurposing more
expensive than it otherwise could be.
Once a drug is chosen, the researcher is able to begin
studying the drug at Phase II clinical trials because the drug has
already undergone basic research, preclinical trials, and (at a
minimum) Phase I clinical trials testing. 34 Much like the process
described above, if the drug survives human clinical trials, then the
researcher can apply for FDA approval and may potentially
receive a patent for the new indication or formulation.
Richard B. Smith, Repositioned drugs: integratingintellectualproperty and
regulatorystrategies, 8 DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES
30

136 (2011).
31 Id
32 Kollewe, supra note 21.

33 Patent thickets are "dense web of overlapping intellectual property rights that
a company must hack its way through in order to actually commercialize new
technology. With cumulative innovation and multiple blocking patents, stronger
patent rights can have the perverse effect of stifling, not encouraging,
innovation." Carl Shapiro, Navigating the Patent Thicket: Cross Licenses,
PatentPools, and StandardSetting, in INNOVATION POLICY AND THE ECONOMY

120 (2001).
34 See Assets & Agreements for NIH-Industry Partnerships,U.S. DEP'T OF
HEALTH & HUM. SERVS., https://ncats.nih.gov/ntu/assets (last updated Nov. 30,
2016). The pharmacological and toxicological data already exists and there is
not much use in recreating it.
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The 21st Century Cures Act,35 which was signed into law
in late 2016,36 further facilitates drug developers' ability to speed
up drug development via repurposing by allowing drug developers
submitting a NDA application to rely upon data and information
previously developed and submitted to the FDA 37 and by allowing
drug developers to submit "data summaries." 3 8 These data
summaries "could include previously submitted data for the same
chemical compound, real world evidence, anecdotal evidence,
insurance data, observational data, and in-house data, such as
evidence of efficacy, safety, and quality."3 9

" 21st Century Cures Act, H.R. 6, 114th Cong. (2016).
6 21st Century Cures Act, CONGRESS.GOV,

https://www.congress.gov/bill/114th-congress/housebill/34/text?q=%7B%22search%22%3A%5B%222 1 st+century+cures+act%22

%5D%7D&r-=1#toc-HO328EF4534A74AO58F979A7D3481A316 (last accessed
Dec. 3, 2016).
37 21st Century Cures Act, H.R. 34, 114th Cong. § 3012 (2016) (as codified in
21 U.S.C. § 529A(b)(1)-(2)).
Sheila Kaplan, Winners and Losers of the 21st Century Cures Act, STAT
(Dec. 5, 2016), https://www.statnews.com/2016/12/05/21st-century-cures-actwinners-losers/.
" Kathryn Brown, 21st Century Cures Act & Its Wide-ReachingImpact, EPULSE NEWSLETTER (Feb. 14, 2017), https://law.depaul.edu/about/centers-andinstitutes/health-law-institute/newsletter/Pages/2017-Jan/2 1 st-Century-CuresAct-and-its-Wide-Reaching-Impact.aspx. Deborah Mazer and Gregory Curfman
argue that the 21st Century Cures Act may actually lower public confidence in
FDA-approved drugs. They explain that the Act's changes to the evidentiary
standard for drug approval, "may have the result of weakening the traditional
standards required by the FDA, with an unpredictable long-term effect on drug
safety and efficacy. Bringing new medical products to market efficiently is a
laudable goal, but the government must carefully walk the fine line between
speed of drug approval and the rigor of the approval process." Deborah Mazer
& Gregory Curfinan, 21st Century CuresAct Lowers Confidence in FDAApproved Drugs and Devices, HEALTH AFF. (Feb. 14, 2017),
38

http://www.healthaffairs.org/do/10.1377/hblog20170214.058710/full/.

They

also indicate that the Act, which "gives substantial discretion to the [HHS]
Secretary to accept, limit, or reject the use of ambiguous 'real-world evidence'

https://via.library.depaul.edu/jatip/vol28/iss1/2
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B. Benefits ofDrug Repurposing
Drug repurposing boasts many advantages over the usual
drug discovery and development process. First, repurposed drug
development takes approximately three to twelve years as opposed
to the twelve to sixteen years necessary in the normal process of
creating a drug from scratch. This shortened time frame is due to
the existing pharmacologic and toxicological data collected during
basic research, preclinical trials, and clinical trials previously
performed on the drug. Given that the data already exists,
researchers skip to Phase II clinical trials and therefore spend less
time and money on research and development.
Through
repurposing, it is estimated that drug developers save forty percent
on the overall cost of bringing a drug to market.4 0 Additionally,
the success rates of receiving FDA approval is two times higher
when repurposing. 41
This is, again, due to the ample
pharmacological, toxicological, and formulation information
already available on the drug. 42
Researchers assess this
information and, based on their knowledge and experience,
determine if there is a reasonable likelihood that the drug could
effectively treat a different disease or illness. The ability to
examine the drug data has led to an approval rate of repurposed
drugs that is nearly two times higher than that of drugs developed
through the usual process. 43

is a "novel departure from the traditional view of the level of evidence that
would be required [to approve a drug]." Id.
40
41

Chong & Sullivan, Jr., supra note 23, at 645.
Ann M. Thayer, DrugRepurposing, 90 CHEM. & ENG'G NEws 15 (2012),

http://cen.acs.org/articles/90/i40/Drug-Repurposing.html?h=-1031248274.
42 RepurposingDrugs, U.S. DEP'T OF HEALTH & HUM.
SERVS.,
https://ncats.nih.gov/preclinical/repurpose#leam-more_(last updated Nov. 9,

2016),
Simon Kremer & Rachel Jones, Old drugs, new tricks: patent considerations
in drug repurposing, LIFE Sc. INTELL. PROP. REv. (Dec. 19, 2014) (republished
43

at LEXOLOGY (Jan. 28, 2015),
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C Drawbacks to Drug Repurposing
Drug repurposing has many benefits, yet there are also a
Scholars have
number of drawbacks to its implementation.
suggested that drug repurposing is itself a market failure.
Professor Benjamin Roin claims that there is little to no incentive
for pharmaceutical companies to repurpose once its drug is
approved and even less incentive to do so once the generic version
is approved.4 4 Further, "[i]t is possible that a large pharmaceutical
company may have known or suspected new and alternative uses
for their patented drug in some cases, but decided not to explore
the less financially lucrative new uses, such as treating rare or
neglected diseases." 4 5 It is also possible that pharmaceutical
companies do not repurpose due to concerns that the repurposing
research will expose adverse effects of the old drug such that it
would necessitate taking the drug off the market and destroy its
profitability.4 6 For example, while studying Vioxx as a possible
treatment for colon polyps, Merck discovered Vioxx increased the
risk of heart attacks and stroke in patients taking the drug.4 7 The
drug was removed from the market after an estimated 20 million
Americans have taken the drug, unknowingly exposing themselves
to the increased risks of heart attack and stroke.4 8 Significant.
consumer backlash resulted in response to these study findings in
the form of thousands of lawsuits.4 9
An additional drawback to drug repurposing is that it does
comparatively little to incentivize the development of orphan
http://www.lexology.com/library/detail.aspx?g-Oell981f-5268-4bOf-b6a61cb27e97e07c.
"Roin, supranote 12, at 2.
45 Sem, supranote 14, at 163-64.
46 Thayer, supra note 41.
4 See Snigdha Prakash & Vikki Valentine, Timeline: The Rise and Fall of
Vioxx, NPR (Nov. 10, 2007),
http://www.npr.org/templates/story/story.php?storyld=5470430.
48 Id
49 Associated Press, Merck Agrees to Settlement Over Vioxx Ads, N.Y. TIMES
(May 21, 2008), http://www.nytimes.com/2008/05/21/business/21vioxx.html.

https://via.library.depaul.edu/jatip/vol28/iss1/2
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drugs. 50 Although repurposing can produce orphan drugs, the
process is not solely directed towards the production of drugs for
rare or orphan diseases. Pharmaceutical companies, given the
choice, would prefer to make a blockbuster drug that will be used
by millions of consumers rather than an orphan drug that reaches a
much smaller segment of consumers. There is a real need to
incentivize the development of orphan drugs; there are over 5,000
rare diseases (and new ones are discovered every week)," but
there are only 575 approved orphan drugs and devices. 52 To
encourage the development of orphan drugs via repurposing, the
FDA created the Rare Disease Repurposing Database which
compiles publicly available information not readily available to
potential developers. 53 While drug repurposing could more
effectively bring orphan drugs to market, there is no extra financial
incentive to do so.
It should also be noted that although drug repurposing's
shortened production cycle could help reduce the price of drugs,
there are no formal industry price constraints.5 4 Pharmaceutical
companies that produce repurposed drugs could still charge the
Orphan drugs are those that treat a condition that affects less than 200,000
people in the United States. Shannon Gibson, Orphan drug incentives in the
pharmacogenomicscontext: policy responses in the US and Canada, 2 J.L.
5o

Biosci. 263 (July 2015).
5

Aarti Sharma et al., Orphan drug: Development trends and strategies, 2 J.

PHARM. BIOALLIED Sci. 290 (Oct.-Dec. 2010).
52 Developing Productsfor Rare Diseases & Conditions, U.S.
ADMIN.,

FOOD & DRUG

http://www.fda.gov/Forlndustry/DevelopingProductsforRareDiseasesConditions
/ucm2005525.htm (last updated Nov. 17, 2016).
* Margaret Foster Riley, An Unfulfilled Promise: ChangesNeeded to the Drug
Approval Process to Make PersonalizedMedicine a Reality, 70 FOOD DRUG L.J.
289, 310 (2015).
54 But see Mark Kessel, The problems with today's pharmaceuticalbusiness-an
outsider'sview, 29 NATURE BIOTECHNOLOGY 27, 28 (Jan. 2011) (noting
informal price constraints exist in the form of regulators and third party payors
(or insurance companies) who "measure what benefits patients are deriving
from the drugs" thus enabling them to "bear down on prices, access, utilization
and prescribing patterns").
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same or inflated prices, thus reaping more profits than normal.
Despite these drawbacks, drug repurposing has been utilized in
several ways.
IV. DRUG REPURPOSING UTILIZATION
In recent years, increasingly more repurposing of old drugs
has occurred.
Better yet, many contemporary, well-known
pharmaceuticals have been repurposed: Cymbalta was developed
as an antidepressant but is now approved to treat fibromyalgia;5 5
Evista is a birth control drug that was repurposed as an
osteoporosis treatment and to prevent breast cancer; 56 and,
tretinoin was originally developed to treat acne and is now also
used to manage acute promyelocytic leukemia. 5 7
This Section reviews how drug repurposing is currently
implemented both in the private and public sector. Part A
discusses how pharmaceutical companies are currently utilizing
repurposing to develop new drugs more quickly. Part B explains
the National Institute of Health (NIH) National Center for
Advancing Translational Sciences (NCATS) Program, which,
through several initiatives, aims to improve the drug repurposing
process.
Part C describes the repurposing work of private
partnerships between researchers and disease advocacy groups,
such as Cures Within Reach. Lastly, Part D examines how blackbox medicine facilitates drug repurposing by identifying potential
connections between existing drugs and new uses.
A. PharmaceuticalCompanies ConductingRepurposing
Despite
companies are
years, "[t]here
companies try

the drawbacks mentioned above, pharmaceutical
no strangers to repurposing; however, in recent
is a greater emphasis [on repurposing] now as
to squeeze more revenue out of their existing

Kollewe, supra note 21.
56

Id

51

J.K. Aronson, Old drugs - new uses, 64 BRITISH J. CLINICAL

PHARMACOLOGY 564 (2007).

https://via.library.depaul.edu/jatip/vol28/iss1/2
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assets."" In a sense, pharmaceutical companies' repurposing their
own drugs is an obvious, financially-smart decision. 59 "Revisiting
shelved compounds is an undertaking without much downside and
one that can help companies feeling the pressures of expiring
patents, high costs, and low productivity. Some firms have cut
back on early R&D and have made repurposing a part of their core
business." 60
To be sure, a considerable amount of "evergreening"
occurs through marginal tweaks to brand-name drugs."' These
minor modifications allow brand-name pharmaceutical companies
to patent the modified drug as new and to gain a resulting
additional twenty years of patent exclusivity. 62 Evergreening and
Thayer, supra note 41.

It should be noted that pharmaceutical companies have an additional
incentive to formally repurpose and approve new treatments for approved drugs.
Pharmaceutical companies cannot formally promote drugs as treatments for
indications for which the drug is not FDA approved. This is called off-label
promotion, and the Food Drug and Cosmetics Act (FDCA) prohibits such action
by prohibiting the introduction of un-approved drugs into interstate commerce.
See 21 U.S.C. § 331(a). The FDA, however, has been largely ineffective in
preventing off-label promotion due to First Amendment protections. See, e.g.,
U.S. v. Caronia, 703 F.3d 149, 168-69 (2d Cir. 2012) (holding truthful off-label
promotion of FDA-approved drugs is not prohibited by FDCA misbranding
provisions). Pharmaceutical companies can avoid off-label promotion violations
by utilizing its previously generated data to submit a new treatment NDA for its
already approved drugs.
60 Thayer, supra note 41.
61 Roger Collier, Drugpatents: the evergreeningproblem, 185 CANADIAN
MED. Assoc. J. E385 (June 11, 2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680578/pdf/185e385.pdf
Evergreening is the development of new drugs by slightly tweaking old drugs.
Id. As one scholar notes, "Because of the huge commitment of time and
resources it takes to obtain FDA approval for a new drug, many pharmaceutical
companies prefer to invest in a safer bet: promoting existing drugs by extending
labels, changing doses, or changing drug combinations for existing treatments."
Franklin Allen & Glenn Yago, FinancingCures, in FINANCING THE FUTURE:
MARKET BASED INNOVATIONS FOR GROWTH (2010).
62 Gaudry, supra note 15,
at 3.
5
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repurposing, though, have distinct purposes. Evergreening is
largely criticized as a practice to raise drug prices, thereby
protecting pharmaceutical company's market exclusivity. It rarely
results in any therapeutic advantage.6 3 Repurposing, by contrast,
seeks to transform existing drugs into a new therapeutic treatment.
Much of the repurposing conducted by pharmaceutical
companies tends to be performed in collaboration with academic
institutions or through industry partnerships. 6 For example,
AstraZeneca, which has been particularly active in partnering for
drug repurposing, partnered with (1) Taiwan's National Research
Program for Biopharmaceuticals to develop drug candidates for
therapies targeting diseases prevalent in Asia, 65 (2) Cancer
Research UK to repurpose an asthma therapy into a treatment for
kidney cancer, 6 6 and (3) Sanofi to provide "free access to 210,000
usually closely guarded compounds . . . [to] diversify . . . "67 the
companies' drug portfolios. Pfizer has also taken an active role in
repurposing its existing drugs for rare diseases through
collaborative efforts within the industry and through the NIH-

63 Aaron Kesselheim et al., Extensions ofIntellectual PropertyRights and

DelayedAdoption of Generic Drugs: Effects on MedicaidSpending, 25 HEALTH
1637 (Nov. 2006); Leigh Purvis & Crystal Kuntz, Is High Prescription
Drug Spending Becoming Our New Normal?, HEALTH AFF. BLOG (May 17,
AFF.

2016), http://healthaffairs.org/blog/2016/05/17/is-high-prescription-drug-

.

spending-becoming-our-new-normal/.
64 See infra notes 65-56, 66-77 and accompanying text.
65 Dave Silver, AstrazenecaAllies with Taiwan in Drug RepurposingProject,
BIOWORLD (Oct. 13, 2013), http://www.bioworld.com/content/astrazenecaallies-taiwan-drug-repurposing-project-1.
66 Emily Mullin, CancerResearch UK will repurpose an AstraZeneca asthma
drugfor kidney cancer, FIERCEBIOTECH (Jan. 3, 2014, 8:00 AM),
http://www.fiercebiotech.com/deals/cancer-research-uk-will-repurpose-anastrazeneca-asthma-drug-for-kidney-cancer.
67 Denise Roland, AstraZeneca, Sanofi Agree to Share ProprietaryCompounds,
WALL STREET J. (Nov. 19, 2015, 7:03 PM),
https://www.wsj.com/articles/astrazeneca-sanofi-agree-to-share-proprietary-

compounds-1447977780.
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Industry Partnership program. 6 8 Additionally, pharmaceutical
companies have begun "licensing potential NCEs [new chemical
entities] from biotechnology companies or universities" that have
already conducted the basic research and pre-clinical trials. 6 9
These strategic partnerships allow pharmaceutical companies to
combine their institutional knowledge in order to identify potential
new treatments for existing drugs.
Further, although Professor Benjamin Roin claims "there is
no viable business model for repurposing old drugs at present," 7 0
the efforts of pharmaceutical companies dedicated to repurposing
would suggest otherwise.
The number of pharmaceutical
companies that exclusively repurpose old drugs is growing to the
tune of three to four new companies each year. 7 1 Smaller
pharmaceutical companies, such as BioVista and SOM Biotech,
are solely dedicated to repurposing existing drugs.
BioVista
systematically studies and develops repositioned drugs for
neurogenerative diseases, epilepsy, oncology, and orphan
diseases. 72
Through its research and development efforts,
BioVista has filed twelve novel use patents on repurposed drugs. 73
SOM Biotech only repurposes drugs to treat rare diseases.7 4

Kevin Lee, RepositioningExisting Drugsfor Rare Diseases, PFIZER, INC. 3,
4, 12 (Apr. 16, 2013), http://www.irdirc.org/wpcontent/uploads/2013/06/Kevin-Lee.pdf.
69 Sem, supra note 14, at 147. New chemical entities are drugs for which the
FDA has not previously approved a drug with the same chemical composition.
The drug is novel, the first of its kind. See New ChemicalEntity Exclusivity
Determinationsfor Certain Fixed-CombinationDrug Products, Guidancefor
Industry, FOOD & DRUG ADMIN. (Oct. 2014),
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformatio
n/guidances/ucm386685.pdf.
70 Roin, supra note 12, at 9.
" Nosengo, supranote 3, at 315.
72 About us, BIOVISTA, http://www.biovista.com/about/ (last accessed. Dec. 2,
6

2016).
73 Id.

74 SOMBiotech, The Drug Repositioning Company, SOM BIOTECH,
http://www.sombiotech.com/ (last accessed Dec. 2, 2016).
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B. National Centerfor Advancing TranslationalSciences

(NCA TS)
In 2012, President Obama provided funding to launch the
NIH's NCATS's Discovering New Therapeutic Uses for Existing
Molecules program." The program's goal is to improve the
process of repurposing drugs and "tackle bottlenecks in drug
development. 7 In order to do so, the program collects drugs to
be included in NCATS's pharmaceutical library, the NCATS
Pharmaceutical Collection. 7
Similar to the pharmaceutical
libraries previously mentioned, researchers are able to access the
NCATS Pharmaceutical Collection to screen drugs for
repurposing. Additionally, in August 2016, the program launched
its Bench-to-Clinic Initiative which is directed at designing a
systematic approach to identifying existing drugs that could be
suitable candidates for repurposing. 78
Perhaps most influential to the progression of drug
repurposing is the program's offering of non-IP incentives to
pharmaceutical companies in the form of grants. In 2013, NCATS
funded nine cooperative agreements between pharmaceutical
companies and academic researchers to conduct repurposing
studies for the discovery of novel therapies for a variety of
diseases. 7 In 2015, NCATS funded another four cooperative

" New Therapeutic Uses in Action, U.S. DEP'T OF HEALTH & HUM. SERVS.,
https://ncats.nih.gov/ntu/about/action (last updated Aug. 30, 2016).
76 Jocelyn Kaiser, Acting DirectorThomas Insel Explains New NIH
TranslationalCenter's Aims and Structure, SCIENCE (Jan. 10, 2012, 10:53 AM),
http://www.sciencemag.org/news/2012/01/acting-director-thomas-inselexplains-new-nih-translational-centers-aims-and-structure.
n Early-StageRepurposing, U.S. DEP'T OF HEALTH & HUM. SERVS.,
https://ncats.nih.gov/preclinical/repurpose/early (last updated Apr. 22, 2015).
78 NCA TS Announces Funding Opportunityfor New Bench-to-ClinicPurposing
Initiative, U.S. DEP'T OF HEALTH & HUM. SERVS. (Sept. 2016),
https://ncats.nih.gov/news/releases/2016/drug-repurposing-bench-to-clinicfunding.
" New Therapeutic Uses 2013 ProjectAwards, U.S. DEP'T OF HEALTH & HUM.
SERVS., https://ncats.nih.gov/ntu/projects/2013 (last updated Sept. 2, 2016).
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agreements. 80
The participating companies include many
pharmaceutical giants, such as GlaxoSmithKline, Pfizer,
AstraZeneca, and Abbott.8 1 Although these studies are not solely
dedicated to finding therapies for rare diseases, many of the studies
are directed towards discovering therapies for tropical or orphan
diseases, such as Chagas disease and glioblastoma.
The NIH-Industry Partnerships effectively unite the
pharmaceutical industry, academic researchers, and the NIH, a
federal agency. 83
Pharmaceutical companies provide the
knowledge about how to make and use the drug, the previous
clinical data (which is not always publicly available), and the drug.
itself Researchers provide knowledge of the disease or illness to
be studied, as well as the manpower to conduct the repurposing
studies. Lastly, the NIH provides the funding necessary to conduct
the repurposing studies. The NIH-Industry Partnerships are not
without their detractors: Roy Vagelos, former Chairman and CEO
of Merck, claims drug repurposing is a "fishing expedition" and
"the NIH [should] not support clinical studies of marketed
drugs." 8 4 Instead, he believes repurposing research and drug
New Therapeutic Uses 2015 ProjectAwards, U.S. DEP'T OF HEALTH & HuM.
SERVS., https://ncats.nih.gov/ntu/projects/2015_(last updated Oct. 11, 2016).
80

81 Minna Allarakhia, Open-source approachesfor the repurposingof existing

orfailed candidatedrugs: learningfrom and applying the lessons across
diseases, 7 DRUG DESIGN, DEV., & THERAPY 753 (Aug. 7, 2013),

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743608/pdf/dddt-7-753.pdf.
One such NIH-Industry Partnership grant funds Steven Grant from Virginia
Commonwealth University, who partnered with AstraZeneca to explore drug
combinations that kill acute myeloid leukemia cells. NACTS Matches
Researchers with PharmaceuticalIndustry Assets to Test Ideasfor New
Therapies, U.S. DEP'T OF HEALTH & HUM. SERVS. (July 24, 2015),
https://ncats.nih.gov/news/releases/2015/ntu-awards.
82 New Therapeutic Uses 2015 ProjectAwards, supra note 80.
8
Brian F. Yagi, Note, Triune Synergy in Biomedical Research: Uniting
PharmaceuticalCompanies, UniversityResearchers, and the NIH Through the
Drug Repurposing Projectat NCATS, 44 WASH. U. J.L. & POL'Y 179, 201

(2014).
84 Budget Hearing of the Dep't of Health and Human Services before the H.

Subcomm. of Labor, Health, and Human Serv. Comm. on Appropriations, 112th
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development should be left to the pharmaceutical companies that
own the drug.85
The studies conducted pursuant to the NIH-Industry
Partnerships use partially developed drugs that the pharmaceutical
company abandoned (meaning the drugs are not FDA approved).
"Participating companies provide pre-clinical and clinical supplies
of drugs and matched placebos to funded investigators [academic
researchers] at no charge." 86 Thus, the studies go directly into
Phase II clinical trials, with the pre-clinical data for the drug
already established. 87
For each the partnership contract, any future intellectual
property rights will be held by the academic institution. This is
legally permissible in accordance with the Bayh-Dole Act of 1980,
which allows university recipients of federal grants to retain
intellectual property rights arising from publicly-funded research."8
Since the university, in all likelihood, will not have the capacity to
manufacture any resulting drug, the university will give the
partnering pharmaceutical company the first chance to license the
drug. 89

Cong. 4 (2012) (statement of P. Roy Vagelos, M.D., President of Merck & Co.,
Inc.),
http://appropriations.house.gov/calendar/eventsingle.aspx?EventlD=281151.
"Trying to find a use for a drug that has not been approved is a fishing
expedition that has a very low possibility of success. As for repurposing of
drugs, I would recommend that the NIH not support clinical studies of marketed
drugs. Such studies that are aimed at obtaining additional claims for drugs
already being sold should be funded by the company that owns the drug and will
benefit
financially for the additional claim." Id.
85
Id.
86 Assets & Agreementsfor NIH-Industry Partnerships,supra note 34.
87 Id
" Bayh-Dole Act of 1980, P.L. 96-517, 94 Stat. 3015 (codified as amended at
35 U.S.C. § 200-212).
" NIH-Industry PartnershipFrequentlyAsked Questions, U.S. DEP'T OF
HEALTH & HUM. SERVS., https://ncats.nih.gov/ntu/about/partnershipsfaq#conclusion (last updated Aug. 31, 2016).
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C. PartnershipsBetween DiseaseAdvocacy Groups and
Researchers: Venture Philanthropy
Historically, disease advocacy groups, such as Cures
Within Reach
and the Alzheimer's Drug Discovery
Foundation, 91 supported individuals suffering from diseases
through charitable contributions to fund the development of cures
and therapies, educational resources, and participant recruitment
for clinical trials.9 2 These groups focused their drug discovery
efforts on both new and repurposed drugs. 93
Believing these contributions were not effectively helping
afflicted individuals, disease advocacy groups began partnering
with private sector bioscience and pharmaceutical companies to
fund basic research and translational research, which is similar to
repurposing. 94 Through these partnerships, disease advocacy
groups are assuming a more active role in drug development by
employing a venture capitalist structure to funding research in
order to achieve their philanthropic goal-discovering a disease
treatment or cure. 9 5 Similar to pharmaceutical libraries which
enable scientists to choose which drugs to repurpose, these
partnerships are facilitated by the creation of "research registries
and biological repositories [that] enable research studies on

Mission andImpact, CUREs WITHIN REACH,
http://www.cureswithinreach.org/about-us (last accessed Dec. 3, 2016).
90

91 About Us, ALZHEIMER'S DRUG DISCOVERY FOUND.,

https://www.alzdiscovery.org/about-addf (last accessed Dec. 3, 2016).
92 Anne M. Readel, Findinga Cure: Incentivizing PartnershipsBetween
DiseaseAdvocacy Groups andAcademic and CommercialResearchers, 26 J.L.

& HEALTH 285, 288 (2013).
9 Id at 288-89.
94 Id. at 290. Similar to repurposing, translational research applies "discoveries
generated during research in the laboratory, and in preclinical studies, to the
development of trials and studies in humans." InstitutionalClinicaland
TranslationalScience Awards, U.S. DEP'T OF HEALTH & HUM. SERVS.,
http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-06-002.html (last accessed
Dec. 2, 2016).
95 Readel, supra note 92, at 288.
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particular diseases." 9 6
These partnerships for basic and translational research, as
well as the disease advocacy groups' historical emphasis on
repurposing research, give disease advocacy groups a strong
foundation upon which they may build.
D. Black-box Medicine
Modem medicine increasingly uses personalized medicine,
a rapidly advancing field of healthcare that tailors treatment to the
individual patient.97 "Black-box medicine," which is the "use of
opaque computational models to make decisions related to health
care,"98 is a growing subset of personalized medicine. Essentially,
black-box medicine utilizes "'predictive analytics,' involving the
use of real time large datasets and predictive algorithms to help
inform treatment decisions, such as who should be sent first to
intensive care units." 99
One legal scholar has suggested black-box medicine could
provide a systematic approach to identifying potential drug
candidates for repurposing.100
The wealth of data available in electronic
health records of patients suffering from
different ailments and responding to
drugs they take for other purposes may be
mined by big-data algorithms, which can
suggest new uses .

black-box

. .

. To the extent that

medicine

identifies

Id. at 298 n.107.
See W. Nicholas Price II, Black-box Medicine, 28 HARv. J.L. & TECH. 419,
421 (2015); see also PersonalizedMedicine, U.S. NEWS & WORLD REPORT,
http://health.usnews.com/health-conditions/cancer/personalizedmedicine/overview (last updated Jan. 20, 2011).
98 Price, Black-box Medicine, supra note 97, at 421.
99 See id. at 421 n.7 (citing Ruben Amarasingham et al., Implementing
Electronic Health Care PredictiveAnalytics: Considerationsand Challenges,
33 HEALTH AFF. 1148, 1148 (2014)).
96
9

100 Id. at 436-37.
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relationships between complex sets of
variables that are largely implicit, blackbox medicine suggests potential new
research pathways to make those implicit
10
connections explicit.o
The NIH seems to agree that black-box medicine could be the
future of drug repurposing. Through NCATS's Bench-to-Clinic
Initiative, the NIH is supporting pre-clinical studies to "test the
utility of [a] . . . computational algorithm or big dataset from
patient records to predict new uses of a drug." 1 0 2 Black-box
medicine, however, is a relatively new concept, and the intellectual
property rights, privacy concerns, and regulation of black-box
medicine currently remains unsettled.10 3
V. REPURPOSING RESEARCH AND PATENT
INFRINGEMENT
Drug repurposing can be performed by the developer of the
For example, GlaxoSmithKline originally
original drug.
developed Zyban to treat depression, but later repurposed the drug
to assist individuals to quit smoking.' 0 4 "More often [repurposing
is performed] in collaboration with academic medicine or others,
and sometimes by developers that have no relationships at all with
the original developer." 10 When the repurposing research is
performed by developers without any relationship to the original
A researcher
developer, complicated patent scenarios arise.'
101

Id
&

New Therapeutic Uses FundingInformation,U.S. DEP'T OF HEALTH
HUM. SERVS., https://ncats.nih.gov/ntu/funding (last updated Nov. 30, 2016).
03 See W. Nicholas Price II, Big Data, Patents, and the Future ofMedicine, 37
102

CARDozO L. REv. 1401 (2016) for a discussion on these issues.
104 Smith, supranote 30, at 135.
105 Foster Riley, supra note 53, at 309.
106 This is presuming that the repurposing research done in collaboration
is
subject to a contract which specifies the rights of the academic or partner
institution.
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conducting repurposing studies on a drug must ensure that he is
not infringing on any patent rights owned by the original developer
of the drug to be studied.
The Drug Price Competition and Patent Term Restoration
Act of 1984 (the "Hatch-Waxman Act")1 0 7 includes a safe harbor
provision for the use of on-patent drugs in drug development
research. The provision states:
It shall not be an act of infringement to
make, use, offer to sell, or sell within the
.

United States . . . a patented invention .

. solely for uses reasonably related to the
development
and
submission
of
information under a Federal law which
regulates the manufacture, use, or sale of
drugs. 108
This statute was passed to allow generic pharmaceutical
companies to more effectively compete with brand-name
companies. Generic pharmaceutical companies previously could
not conduct research and development on the patented drug
without infringing on the patent, so the generic pharmaceutical
companies were reduced to waiting until the patent expired. After
the patent had expired, "the generic company still needed to do
many years of research and clinical studies before they could enter
the market with their generic version of the drug."1 09 Although the
statute is intended to support generic research, the language of the
10
statute can be expansively read to apply to repurposing research.o
Such broad language could protect a drug developer as the
language is not limited to only generic drugs.
The United States Supreme Court has not explicitly stated

107 Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L.
No. 98-417, 98 Stat. 1585 (codified as amended 35 U.S.C. § 271(e)(1)) (1984)
108 35 U.S.C. § 271(e)(1) (2006).
109 Sem, supra note 14, at 152.
11o Id (noting courts have opted for a broad, expansive reading of the safe
harbor protection).
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"

that the provision applies to both generic and repurposing research;
however, it also has not limited the application to only generic
drug research. Instead, the Supreme Court held in Merck KGaA v.
Integra Lifesciences I, Ltd.," I that "the use of patented compounds
in pre-clinical studies is protected under § 271(e)(1) as long as
there is a reasonable basis for believing that the experiments will
produce 'the types of information that are relevant to an IND
[investigational new drug application] or NDA."' 1 2 The Court
further held that
§ 271(e)(1) protection extends to
"experimentation on drugs that are not ultimately the subject of an
FDA submission."' As such, research using on-patent drugs is
permissible so long as the research is "reasonably related to the
development and submission of information to the FDA."ll 4
Ultimately, in order to avoid a claim of patent infringement, "[a]ll
that is required is that the researcher had a 'reasonable basis for
believing that a patented compound may work' in clinical
studies."'
Application of the Hatch-Waxman Act and case law to
drug repurposing shows that repurposing of on-patent drugs will
likely not be considered patent infringement. First, a researcher
conducting a repurposing study must demonstrate that he chose the
drug to be repurposed because, based on the clinical data, he
reasonably believed the drug could be useful in treating a specific
disease or illness." 6 It is highly likely that the researcher will
always have a scientific reason for choosing the drug to be
repurposed-presumably based on the pharmacological and
toxicological drug data and knowledge about the target disease or
illness. Further, it would be illogical, as well as a waste of time
and money, for a researcher to randomly choose a drug to study
from a pharmaceutical library for a new therapeutic use without

.. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005).
112 Id. at 208 (citing Brief of United States as Amicus Curiae 23).
113
114

Id. at 206.
Id

" Sem, supra note 14, at 160 (citing Merck KGaA v. Integra Lifesciences I,
Ltd., 545 U.S. 193, 207 (2005)).
116

Id.
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any reasonable belief that a successful drug will be ultimately be

developed.
Second, a researcher conducting the study must
demonstrate that the information derived from the study was
relevant to a FDA filing, such as a NDA.
The researcher
conducting the repurposing study will want to receive FDA
approval for any drug that is developed, and therefore will want to
file an NDA. If a NDA is filed, any information derived from the
clinical trials regarding the safety and efficacy of the drug will be
included in the application.'" Thus the study and the information
derived from it will be relevant to a FDA filing. Despite the lack
of explicit protection under the Hatch-Waxman Act, repurposing
studies "are largely protected from patent infringement suits under
the § 271(e)(1) safe harbor protections.""
VI. OBTAINING MARKET EXCLUSIVITY
A major hurdle to the development of repurposed drugs is
the. lack of exclusivity. If pharmaceutical companies cannot obtain
market exclusivity for a repurposed drug, then the company will
likely not pursue repurposing. Due to the high cost of drug
research and development, in order for a pharmaceutical company
to bring a drug to market, it must be able to recoup research and
development expenses and profit from the drug sales. To
incentivize drug development, pharmaceutical companies are
given market exclusivity as a reward for drug innovation. The
market exclusivity prevents competitor drugs from entering the
market, which enables pharmaceutical companies to recoup its
losses and profit from the drug.
The high cost of drug development, however, also tends to

i1 See New DrugApplication (NDA), U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopeda
ndapproved/approvalapplications/newdrugapplicationnda/default.htm (last
updated Mar. 29, 2016) (The goal of the NDA is to provide enough information
to the FDA such that the agency can determine whether the drug is safe and
effective.).
118 Sem, supra note 14, at 166.
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be the rationale for charging such high prices for drugs.
Companies justify their prices by explaining that "[i]t costs a lot of
money to invent a medicine and bring it to the market, so the
prices have to be high or the companies will be unable to continue
their important research and development."' 19 Repurposed drugs
should allow pharmaceutical companies to lower drug prices
because the company is spending less on research and
development yet still potentially receiving twenty years of patent
exclusivity in addition to FDA exclusivity.
This Section first discusses the different FDA exclusivity
available for repurposed drugs and then turns to the various kinds
of patents a developer could seek for a repurposed drug so as to
receive patent exclusivity.
A. FDA Exclusivity
Under the current drug approval regime, there are three
kinds of FDA regulatory exclusivity that a repurposed drug could
receive: new use exclusivity, NCE exclusivity, and orphan drug
exclusivity.1 20 Under the Food, Drug, and Cosmetic's Act §
501(b)(2), 12 1 a new use or formulation provides three years of
market exclusivity. New use exclusivity is granted for a drug that
provides a new indication, dosage, strength, form, or delivery
method of an existing drug.12 2 A repurposed drug may receive
new use exclusivity of three years if it alters the old drug in at least
one of these ways. 23
Under the Food, Drug, and Cosmetics Act § 501(b)(1), 2 4 a
NCE provides the holder of an approved NDA five years of market

"9 Sarah Boseley, Big Pharma's worst nightmare, THE GUARDIAN (Jan. 26,
2016), https://www.theguardian.com/society/2016/jan/26/big-pharmas-worstnightmare.
120 Emily Michiko Morris, The Myth of Generic Competition Under the Hatch-

Waxman Act, 22 FoRDHAM INTELL. PROP. MEDIA & ENT. L.J. 245 (2012).
121

122
123

124

21 U.S.C. § 355(b)(2) (2016).
Smith, supra note 30, at 134.
Id
21 U.S.C. § 355(b)(1) (2016).
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exclusivity. 125 NCE exclusivity is granted to a drug with an active
pharmaceutical ingredient (API) that is not already FDA
approved. 1 2 6 In order to receive NCE exclusivity, the repurposed
drug must alter the old drug's chemical composition such that the
repurposed drug's API is innovative. 1 27
Finally, under the Orphan Drug Act, 1 28 an approved orphan
drug provides a drug developer with seven years of market
exclusivity.1 29 Orphan drug exclusivity is only granted to drugs
that treat orphan diseases; 13 thus, for a repurposed drug to receive
orphan drug exclusivity, it must treat an orphan disease. Although
developers of repurposed drugs can likely receive FDA
exclusivity, three to five years, or even seven years, this
exclusivity may still be insufficient to recoup developers' financial
investment. Instead, development of repurposed drugs will likely
hinge on the drug's patentability.' 3
B. PatentExclusivity
Drug developers can also gain market exclusivity through
patent protection. Patents provide twenty years of exclusivity.
Developers typically receive patents eight to ten years before the
drug is FDA approved, leaving approximately ten to twelve years
of exclusivity remaining when the drug hits the market. 132
125 Smith, supra note 30, at 134.
126 Id; Small Business Assistance: FrequentlyAsked

Questionsfor New Drug
ProductExclusivity, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssista
nce/ucm069962.htm (last updated Feb. 11, 2016). This is similar to the novelty
requirement for patent eligibility.
'

Smith, supra note 30, at 134.

Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049, 2051 (1983).
Smith, supranote 30, at 134.
1" Patents and Exclusivity, U.S. FOOD & DRUG ADMIN. 2 (May 19,2015),
http://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusine
ssassistance/ucm447307.pdf.
128

129

13

Israelsen, supra note 25.

132 Alfred Engelburg, How Government Policy Promotes High Drug Prices,
HEALTH AFFAIRS BLOG (Oct. 29, 2015).
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Repurposing expedites the drug development process, so new
drugs enter the market sooner, and they are able to use more of the
market exclusivity provided by the patent.
i.

Patent Eligibility

To receive a patent, an invention must meet the patent
eligibility requirements of non-obviousness, novelty, and
usefulness1 3 3 and cannot be a law of nature, physical phenomena,
or an abstract idea (the "Chakrabarty factors").1 34 Obviousness
means that "an invention must not have been obvious to one with
ordinary skill in the art to which the subject matter of the invention
pertains . .
and in light of the teaching of prior art."l 3 5 Novelty
means the invention was new at the time of discovery,' 36 and
useful means it somehow benefits society. 1 3 7
To patent any repurposed drug, the drug must be nonobvious, novel, and useful. Patent eligibility will differ based on
the drug being analyzed;' 3 8 however, because a repurposed drug is
necessarily a physical object produced through a systematic
process, a developer will not encounter any eligibility problems
with respect to the Chakrabarty factors. Two kinds of patents
typically protect pharmaceutical innovations: composition of
matter and method of use patents. 139 A repurposed drug can be
protected by either, or both, kinds of patents.

35 U.S.C. §§ 101-103 (2016).
134 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
135 DONALD S. CHISUM, CHISUM ON PATENTS § 5.01 (2016).
136 Id. § 3.01.
137 Id § 4.01.
138 The analysis of whether a repurposed drug may be patented
will be
conducted on every repurposed drug that a developer wishes to patent, because
no drug will (or can be) exactly the same.
133

139 Tahir Amin & Aaron Kesselheim, SecondaryPatentingofBranded
Pharmaceuticals:A Case Study on Two HIVDrugs CouldBe Extendedfor

Decades, 31 HEALTH AFF. 2286 (2012).
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Composition of Matter Patent

Composition of matter patents protect "all compositions of
two or more substances," 1 4 0 also known as the API and the drug's
unique chemical formulations. In order to receive a composition
of matter patent, a repurposed drug faces a major roadblock:
establishing novelty. The old drug's API already exists, so in order
for a repurposed drug to receive a composition of matter patent,
the repurposed drug must have a novel API. This means the
developer must manipulate the old drug's API such that new
repurposed drug's API is a new chemical compound. At the same
time, the new API or chemical formulation must still be nonobvious and useful. If it is obvious or not useful, then the
repurposed drug will not be patent eligible.
Composition of matter patents generally provide the
strongest protection for pharmaceuticals because it prevents others
from using the API for any purpose.14 1 Richard Smith, an attorney
whose practice focuses on representing life science companies,
notes, however, that "[t]he success of such composition of matter
patents in protecting the repositioned drug product will depend in
large part on the availability of generic products that can be
substituted through off-label use to achieve the same therapeutic
result as the repositioned product."l4 3
The requirements for FDA NCE exclusivity are quite
similar to the composition of matter patent requirements in that
both exclusivity regimes require the API to be novel. Therefore, if
a repurposed drug's API is not novel, then a developer will receive
neither a composition of matter patent, nor NCE exclusivity. For
example, Mozobil was originally indicated as an inhibitor for HIV
infection (it never launched on the market) and was repurposed to
treat multiple myeloma, a cancer that forms in the white blood

Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980).
Smith, supra note 30, at 131.
142 RichardB. Smith, MCDERMOTT
WILL & EMERY,
https://www.mwe.com/en/team/s/smith-richard-b (last accessed Dec. 3, 2016).
14 Smith, supra note 30, at 133.
140
141

https://via.library.depaul.edu/jatip/vol28/iss1/2
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cells causing cancer cells to build up in the bone marrow. 14 4
Mozobil's repurposed treatment was used in combination with GCSF (a protein that makes white blood cells for bone marrow) 145 to
mobilize haematopoietic stem cells (cells that can develop into
blood cells) 14 6 to treat multiple myeloma. 147 In 2008, the FDA
granted NCE exclusivity for Mozobil, which expired in 2013, and
the developer received a composition of matter patent that will
expire in 2023.148 If Mozobil's new API was not innovative, then
it could not have received protection under either type of
exclusivity.
iii.

Method of Use Patents

Method of use patents protect the use of the API to treat a
specific disease and the method of dosing a patient. 1 49 The API
itself need not be novel, just the indication for which the API is
being used. A repurposed drug can receive a method of use patent
when the repurposed drug treats a new indication or a new method
of dosing a patient. Again, the new indication or method of dosing
must still be non-obvious and useful. In the event that the new
indication was obvious or not useful, a repurposed drug will not be
patent eligible.
In order to establish non-obviousness, drug
developers filing for a method of use patent for a repurposed drug
must surpass the "obvious to try doctrine."
The doctrine,
Mayo Clinic Staff, Diseases and conditions:Multiple Myeloma, MAYO
(Dec. 4, 2015), http://www.mayoclinic.org/diseases-conditions/multiplemyeloma/basics/defmition/con-20026607.
145 Granulocyte colony stimulatingfactor (G-CSF), CANCER RESEARCH UK,
http://www.cancerresearchuk.org/about-cancer/cancers-ingeneral/treatment/cancer-drugs/gcsf (last accessed Dec. 3, 2016).
146 NCI Dictionary of Cancer Terms, NAT'L CANCER INST.
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=693540
(last accessed Dec. 3, 2016).
147 Smith, supra note 30, at 132.
148 Patent and Exclusivityfor: N022311, U.S. FOOD & DRUG ADMIN.,
http://www.accessdata.fda.gov/scripts/cder/ob/patent info.cfn?ProductNo=00
1&ApplNo=02231 1&Appl type=N (last accessed Dec. 3, 2016).
149 Smith, supra note 30, at 133.
144

CLINIC
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established in KSR International v. Telefex, holds that a patent
claim can be proven obvious by showing that the combination of
elements used in the invention was obvious to try.o This means
that if a person having ordinary skill in the art would have tried the
new method of dosing or tried combining the API to treat the new
indication, then the repurposed drug will be considered obvious
and thus patent ineligible.
Method of use patents tend to provide less protection to
drug developers because they do not prevent competitors from
selling the drug for other indications (provided the drug is offpatent for those other indications).' 5 ' Although discovering new
indications may be scientifically easier than discovering a new,
safe, and effective API (for which the developer could receive a
composition of matter patent), drug developers may be wary of
doing this due to the less robust patent protection the developer
would receive under a method of use patent. Further, in the event
that a drug developer receives a method of use patent for a new
indication or method of dosing, the developer may have to contend
with existing patents on the original drug. This could "prevent the
discoverer of a new method of treatment from marketing that
treatment without a license from the owner of the patent on the
drug." 152
A drug developer conceivably could receive both
composition of matter and method of use patents. For example,
the developer of Mozobil received a composition of matter patent,
NCE exclusivity, as well as a method of use patent for the
iso

KSR Int'l v. Teleflex, 550 U.S. 398, 421 (2007); 2141 Examination

Guidelinesfor DeterminingObviousness Under 35 U S.C. 103 [R-07.205],
USPTO.Gov, https://www.uspto.gov/web/offices/pac/mpep/s2141.html (last

updated Nov. 4, 2015).
s' Rebecca S. Eisenberg, PharmaceuticalInnovation and Cost: An American
Dilemma: The Problem ofNew Uses, 5 YALE J. HEALTH POL'Y L. & ETHICS

717, 724 (2005) (citing Allergan Inc. v. Alcon Labs. Inc., 324 F.3d 1322 (Fed.
Cir. 2003)).
I2
James R. Whittle, Note, Tailored Treatment, TailoredEnforcement:
ProtectingInnovation in PersonalizedMedicinefrom a Patent-Protection

Loophole, 84 GEO. WASH. L. REv. 480, 488 (2016); Eisenberg, supra note 151,
at 724 (citing In re Marshall, 578 F.2d 301, 304 (C.C.P.A. 1978)).
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mobilization of the haematopoietic stem cell, which expires in
2023.153 With such market exclusivity, a drug developer may find
it worthwhile to license the original drug to exercise the method of
use patent.
VH. ROOM TO GROW
There are many areas in which the industry can be
improved so as to facilitate more drug repurposing, including
greater access to data, identifying alternative incentives to
repurpose, and clarifying the drug repurposing regulatory regime.
A. More Access to Data
Currently, data sharing is not required in the
pharmaceutical industry, and the pharmaceutical industry is very
competitive by nature. "Pharmaceutical manufacturers, like other
businesses, keep many details of their research and development
(R&D) secret to gain and preserve a competitive advantage."l 5 4
The identification of potential uses of old drugs, however, can only
be done by understanding the pharmacologic and toxicological
drug factors.' For approved drugs, this data is held with the
FDA. The data is also sometimes published in publicly available
open science journals, such as PLoS.15 6 The industry is "less
forthcoming, however, when disclosing the thousands of 'failed'
drug assets to the wider research community. . . . [F]or drug
repurposing of failed compounds to truly realize its potential,
additional mechanisms need to be found that incentivize both large

15 Smith, supra note 30, at 132; Patent andExclusivityfor: N022311, supra
note 148.
154 Aaron S. Kesselheim & Michelle M. Mello, ConfidentialityLaws
and
Secrecy in Medical Research: Improving Public Access to Data on Drug Safety,

26 HEALTH

AFFAIRS

483 (Mar. 2007).

s Foster Riley, supra note 53, at 309.
15
See id. at 310; see PLoS Open for Discovery, PLOS, https://www.plos.org/
(last accessed Dec. 3, 2016).
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and small companies to release data." 1 57 Understandably, the idea
of open source data for repurposing would receive resistance from
pharmaceutical companies; however, pharmaceutical companies
may be more forthcoming if they were compensated for disclosing
failed drugs to a government pharmaceutical library.
Additionally, the creation of a comprehensive database
containing the pharmacological and toxicological data for drugs in
every pharmaceutical library would assist researchers in finding
different disease targets for which a drug may be used."'s Drug
data is held either in the various pharmaceutical libraries (for
which access can cost as much as $5,000), 159 by the
pharmaceutical company, by the FDA, or is publicly available in
scientific literature. Collecting the data in one place would greatly
ease and increase a researcher's ability to identify target diseases.
An alternative option to a comprehensive database would be to
allow open access (or a minimal fee) to pharmaceutical libraries.
Currently, the libraries require researchers to purchase the drug in
order to acquire it.1 6 0

B. CreatingNew andAdditional Incentives
Literature focuses on intellectual property rights and FDA
regulatory exclusivity as the main drivers of drug repurposing
research and development; however, there is debate as to what
other incentives could properly motivate the pharmaceutical
industry to invest in drug repurposing. 16 1 Bruce Bloom, President
and Chief Science Officer of Cures Within Reach, asserts
' Editorial, Bring Out Your Dead, 33 NATURE BIOTECHNOLOGY 1 (Jan. 9,
2015), http://www.nature.com/nbt/joumal/v33/nl/pdf/nbt.3123.pdf.
158 Chong & Sullivan, supra note 23, at 646.
160

Id
See, e.g., Smith, supra note 30, at 131; Sem, supra note 14, at 152; Stephen
Naylor et al., TherapeuticDrugRepurposing, RepositioningandRescue Part IH]
market exclusivity using IntellectualPropertyand regulatorypathways, DDW
(Summer 2015), http://www.ddw-online.com/drug-discovery/p274232therapeutic-drug-repurposing:-repositioning-and-rescue.html; Kremer & Jones,
supra note 43.
161
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"government incentives focused on rare diseases will fuel this
industry repurposing revolution."' 6 2 Mr. Bloom, however, does
not specify what those incentives should be - whether it be grants,
prizes, tax incentives, or extended market exclusivity.
Some scholars argue that offering prizes1 6 3 could prove to
be an additional financial motivator for drug developers to utilize
drug repurposing so as to develop new drugs.1 64 Prizes, which are
conditioned on delivering the specified invention, 165 would
motivate drug developers to repurpose in order to receive the prize
(money).
These scholars claim that a prize system would
encourage pharmaceutical companies to repurpose drugs because
the government would offer prizes for new uses of old drugs based
on the indications' social value.1 66 Professor Roin doubts the
effectiveness of such a system. He claims prize payouts would be
based on the drug's sales volume which "would conflate sales for
the old and new uses, much like monopoly rights that block
generic entry." 67 There is little agreement on which additional
incentives will properly motivate pharmaceutical companies.

162

Bruce E. Bloom, Recent successes andfuturepredictionson drug

repurposingfor rare diseases, 4 EXPERT OP. ON ORPHAN DRUGS 1, 3 (2016).
163 Prizes are payments funded out of general revenue that is made to a drug
developer conditional on delivering the specified invention. See Nancy Gallini
& Suzanne Scotchmer, 2 IntellectualProperty: When is it the Best Incentive
System?, in INNOVATION POLICY AND THE ECONOMY 53 (2002). Prizes are
frequently utilized by the federal government. See generally Challenges, U.S.
GEN. SERV. ADMIN., https://www.challenge.gov/list/ (last visited Apr. 16, 2017).
164 AIDAN HOLLIS & THOMAS POGGE, THE HEALTH IMPACT FUND: MAKING

&

NEW MEDICINES AVAILABLE FOR ALL 14-15, 17 (2008); William Fisher

Talha Syed, Prizes, 43, 46 (2012),
http://cyber.law.harvard.edu/people/tfisher/DrugsChapter7.pdf
165 Gallini & Scotchmer, supra note 163, at 53.
166 Roin, supra note 12, at 1051 (citing AIDAN HOLLIS & THOMAS POGGE, THE
HEALTH IMPACT FUND: MAKING NEW MEDICINES AVAILABLE FOR ALL 14-15,

17 (2008) and William Fisher & Tatha Syed, Prizes 43 & 46 (2012),
http://cyber.law.harvard.edu/people/tfisher/Drugs

Chapter7.pdf)).

167 Id
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C. Clarificationof the Regulatory Regime
As previously discussed, there is no explicit regulatory
guidance regarding how drug developers may gain FDA approval
for repurposed drugs or avoid patent infringement when
conducting repurposing research. Instead, drug developers rely on
the ambiguities of the Hatch-Waxman Act's safe harbor provision
to protect their repurposing research from claims of infringement.
The Hatch-Waxman Act, however, was intended to create a
regulatory regime for generic drugs, not for repurposed ones. 16 8
Nonetheless, drug developers may likely receive FDA
guidance on the use of real life data in drug approval applications.
As previously discussed, the 21st Century Cures Act' 6 9 facilitates
the submission of data summaries 1 70 of real life data and data
previously submitted to the FDA'' for NDA applications. 1 7 2 The
FDA's deliverable schedule for the implementation of the 21st
Century Cures Act provides for the development of a plan,
framework, draft guidance, and revised draft or final guidance
related to the use of real world evidence. These deliverables,
however, currently have no statutory deadline for completion.1 73

168 Sem, supra note 14, at 152.

169 21st Century Cures Act, H.R. 6, 114th Cong. (2016).
170 Kaplan, supra note 38.

17' 21st Century Cures Act, H.R. 34, 114th Cong. § 3012 (2016) (as codified in
21 U.S.C. § 529A(b)(1)-(2)).
172 21st Century Cures Act, H.R. 34, 114th Cong. § 3012 (2016) (as codified
in
21 U.S.C. § 529A).
" 21st Century Cures Act Deliverables,U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Regulatorylnformation/LawsEnforcedbyFDA/SignificantA
mendmentstotheFDCAct/2 1 stCenturyCuresAct/ucm5 62475.htm (last updated

Nov. 5, 2017).

J.D. 2017, DePaul University College of Law. This Article was written for
DePaul University College of Law's Fall 2016 Health Innovation and
Intellectual Property course.
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So while the FDA intends to provide guidance, it is unknown
when the industry may expect such.
VIH.

CONCLUSION

Drug repurposing has the potential to bring drugs to market
more quickly, inexpensively, and successfully than before.
Despite the lack of a regulatory regime directed explicitly towards
drug repurposing, industry players seemingly have not been
deterred from engaging in the practice. To encourage increased
participation in repurposing, the industry needs wider access to
data, new and additional incentives, and a clear intellectual
property and regulatory regime.
Kathryn Brown*
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